Supplementary Figure 4 from A Phase I Clinical Trial Adding OX40 Agonism to <i>In Situ</i> Therapeutic Cancer Vaccination in Patients with Low-Grade B-cell Lymphoma Highlights Challenges in Translation from Mouse to Human Studies

DOI: 10.1158/1078-0432.28523428 Publication Date: 2025-03-03T08:57:37Z